Dose escalation: COM902 monotherapy. + Cohort expansion: COM902 (RDFE) monotherapy. + Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Trial Timeline
Mar 31, 2020 → Dec 30, 2025
NCT ID
NCT04354246About Dose escalation: COM902 monotherapy. + Cohort expansion: COM902 (RDFE) monotherapy. + Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
Dose escalation: COM902 monotherapy. + Cohort expansion: COM902 (RDFE) monotherapy. + Cohort expansion: COM902 in combination with COM701 (both at the RDFE). is a phase 1 stage product being developed by Compugen for Advanced Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04354246. Target conditions include Advanced Cancer, Ovarian Cancer, Lung Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04354246 | Phase 1 | Active |
Competing Products
20 competing products in Advanced Cancer